Allogene Therapeutics (ALLO) Stock

Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed.

ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%.

Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordination with Roche.

SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #calix--Today, Calix, Inc. (NYSE: CALX) reaffirmed the power of its cloud-and-software broadband platform to enable customers to simplify their business, innovate for their subscribers, and grow value for themselves and their communities. Supported by a trusted 15-year partnership, last week ALLO Communications and Calix conducted a 50G PON trial within the ALLO production network in Lincoln, Nebraska. The introduction of 50G PON on the Calix Broadband Platform will e.

FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout the development process SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma.

Penny stocks are some of my favorite stocks to watch.